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Organ doses from hepatic radioembolization with 90Y, 153Sm, 166Ho and 177Lu:
a Monte Carlo simulation study using Geant4
Abstract
90Y-radioembolization is a palliative treatment for liver cancer. 90Y decays via beta emission, making
imaging difficult due to absence of gamma radiation. Since post-procedure imaging is crucial, several
theranostic radionuclides have been explored as alternatives. However, exposures to gamma radiation
throughout the treatment caused concern for the organs near the liver. Geant4 Monte Carlo simulation
using MIRD Pamphlet 5 reference phantom was carried out. A spherical tumour with 4.3cm radius was
modelled within the liver. 1.82GBq of 90Y sources were isotropically distributed within the tumour, with no
extrahepatic shunting. The simulation was repeated with 153Sm, 166Ho and 177Lu. The estimated
tumour doses for all radionuclides were 262.9Gy. Tumour dose equivalent to 1.82GBq 90Y can be
achieved with 8.32, 5.83, and 4.44GBq for 153Sm, 166Ho and 177Lu, respectively. Normal liver doses by
the other radionuclides were lower than 90Y, hence beneficial for normal tissue sparing. The organ doses
from 153Sm and 177Lu were relatively higher due to higher gamma energy, but were still well below 1Gy.
166Ho, 177Lu and 153Sm offer useful gamma emission for post-procedure imaging. They show potential
as 90Y substitutes, delivering comparable tumour doses, lower normal liver doses and other organs
doses far below the tolerance limit.
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Abstract. 90Y-radioembolization is a palliative treatment for liver cancer. 90Y decays via beta
emission, making imaging difficult due to absence of gamma radiation. Since post-procedure
imaging is crucial, several theranostic radionuclides have been explored as alternatives.
However, exposures to gamma radiation throughout the treatment caused concern for the organs
near the liver. Geant4 Monte Carlo simulation using MIRD Pamphlet 5 reference phantom was
carried out. A spherical tumour with 4.3cm radius was modelled within the liver. 1.82GBq of
90
Y sources were isotropically distributed within the tumour, with no extrahepatic shunting. The
simulation was repeated with 153Sm, 166Ho and 177Lu. The estimated tumour doses for all
radionuclides were 262.9Gy. Tumour dose equivalent to 1.82GBq 90Y can be achieved with 8.32,
5.83, and 4.44GBq for 153Sm, 166Ho and 177Lu, respectively. Normal liver doses by the other
radionuclides were lower than 90Y, hence beneficial for normal tissue sparing. The organ doses
from 153Sm and 177Lu were relatively higher due to higher gamma energy, but were still well
below 1Gy. 166Ho, 177Lu and 153Sm offer useful gamma emission for post-procedure imaging.
They show potential as 90Y substitutes, delivering comparable tumour doses, lower normal liver
doses and other organs doses far below the tolerance limit.

1. Introduction
Liver cancer is the second most common cause of death from cancer worldwide [1]. Radioembolization
is widely used for palliative treatment of hepatocellular carcinoma (HCC), which is the most common
type of liver cancer. The procedure involves intra-arterial administration of embolic Yttrium-90 (90Y)
microparticles directly to the tumour, delivering all the radiation in-situ. Two commercial radioembolic
agents are available, the glass-based TheraSphere® (Nordion, Canada) and the resin-based SIR-Spheres
(SIRTex, Australia) microspheres. 90Y decayed 99.98 % via beta emissions, thus considered as a pure
beta emitter. Since gamma emission is absent, verification of 90Y-microsphere distribution following
each procedure is a challenge. The post-procedure imaging is crucial for patient monitoring, in case
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there is presence of extrahepatic deposition of the microparticles. Bremsstrahlung imaging can be
utilised, but the images are very poor in resolution.
Several theranostic (therapy and diagnostic) radionuclides have been suggested as 90Y alternative [25]. These include Samarium-153 (153Sm), Holmium-166 (166Ho), and Lutetium-177 (177Lu). The physical
characteristics are tabulated in table 1. Due to the presence of gamma emissions throughout the length
of the treatment, the exposure from gamma radiation towards the organs in the proximity of the liver
has been a concern. Moreover, in order to achieve similar therapeutic effect as 90Y, higher activities may
be required, increasing the gamma exposure to these organs. The aim of this study was to estimate the
absorbed dose to these organs from the exposure of gamma radiations by the alternative radionuclides,
as compared to 90Y for hepatic radioembolization. The Geant4 Monte Carlo code was used to simulate
the treatment.
Table 1. Physical characteristics of suggested radionuclides for radioembolization [6].
Radionuclides

90

153

166

177

Physical half-life, T1/2 (days)

2.67

1.93

1.12

6.65

2279.8 (99.98)

807.6 (19.5)

1854.5 (48.2)

498.3 (79.3)

Principal Eγ (keV) (% yield)

-

103.2 (29.2)

80.6 (6.6)

208.4 (10.4)

Maximum beta range (mm) in soft tissue

11.4

4.0

9.3

2.5

Maximum

Eβ-:

Eβ-

Y

(keV) (% yield)

Sm

Ho

Lu

energy of beta; Eγ : energy of gamma

2. Materials & Methods
2.1. Simulation with 90Y
Monte Carlo simulation using Geant4.9.6.p03 advanced example human_phantom was carried out. The
70 kg, 1.74 m tall human phantom adopted from MIRD Pamphlet 5, and a spherical tumour of radius r
= 4.3 cm, simulated within the liver volume are shown in figure 1 (a) and (b), respectively. The tumour
size was chosen since it was the largest spherical tumour able to be constructed within the liver, without
interceptions between the tumour and liver boundaries. The tumour and liver volumes are 333 and 1833
cm3, respectively, which correspond to 18.2 % tumour involvement.

(b)

Figure 1. (a) The MIRD Pamphlet 5 [7]
phantom with (b) spherical tumour
constructed within the liver, as
modelled and visualised using Geant4.

(a)

The total activity, A of 1.82 GBq 90Y was prescribed to the tumour, as determined using equation (1)
[8], which incorporates the Body Surface Area (BSA) value calculated from equation (2) [9]. The 90Y
sources were assumed to be fully taken by the tumour, with no lung and extrahepatic shunting. The
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number of events, N corresponding to the total 90Y activity was 6.07 x 1014 events, as determined using
equation (3) where decay constant, λ of 90Y is 3.00 x 10-6 s-1.

A (GBq) = BSA (m2 ) - 0.2 + ( % tumour involvement / 100)

(1)

BSA (m2 ) = 0.20247 × height 0.725 (m) × weight 0.425 (kg)

(2)

A (Bq) = λ (s-1 ) N

(3)

The electromagnetic interactions of particles were modelled using the Low Energy Livermore and
Radioactive Decay Physics List. The threshold of production of secondary particles was fixed to 1 mm.
The Geant4 General Particle Source was used to generate the decay of the radionuclide in the tumour.
90
Y point-like sources were isotropically distributed within the tumour volume with randomised
direction of emissions. Approximately 6.07 × 107 events were generated in each simulation to obtain a
statistical accuracy of less than 1 % in the results. The energy deposited (MeV) to all organs were
multiplied to 107, converted to Joules (J), and divided by each organ mass (kg) to obtain the total
absorbed dose (Gy).
2.1.1. Comparison between Geant4 and the partition model. The tumour absorbed dose calculated by
means of Geant4 was compared to the tumour dose estimated using the MIRD based partition model
[10] as shown in equation (4). This was done to quantify the agreement between the two models for
internal dosimetry.

Absorbed dose (Gy) =

49670  A (GBq)
mass (g)

(4)

2.2. Simulations with 153Sm, 166Ho and 177Lu.
2.2.1. Determination of dose factor. The activities corresponding to 107 events calculated using
equation (3), are shown in table 2 for each radionuclide. A pilot run simulation with 107 events,
uniformly distributed throughout the liver volume were carried out for each radionuclide. The energy
deposited (J) to the liver were converted to absorbed dose (Gy) and divided by the corresponding activity
to obtain the dose per activity (Gy/GBq) for each radionuclide. The dose per activity value was then
normalised to that of 90Y to obtain the dose factor.
Table 2. Radionuclide activity corresponding to 1 × 107 events.
Radionuclides

Decay constant, λ (s-1)

Corresponding activity, A (Bq)

90

3.00E-6

30

Y

153

Sm

4.16E-6

41.6

166

Ho

7.18E-6

71.8

177

Lu

1.21E-6

12.1

2.2.2. Simulations with other radionuclides as compared to 90Y. The total 90Y activity of 1.82 GBq were
divided by each dose factor to determine the activity needed for each radionuclide to deliver identical
tumour dose as 90Y. These activities were then applied into the tumour and the simulation setup as in
section 2.1 were repeated for each radionuclide. The dose to the tumour, normal liver and other organs
were recorded and compared with 90Y.
3. Results and discussion
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The activity of each alternative radionuclide used to achieve the same tumour dose of (262.9 ± 0.6) Gy,
are shown in table 3. The dose estimated using the partition model was 271.5 Gy. The 3 % dose
difference between the two methods can be explained due to presence of cross-over radiation at the
tumour edge, which escaped from the tumour volume and recorded by the Geant4 simulation. This
fraction of radiation was neglected by the partition model because of the assumption that beta particles
are fully absorbed by the source volume, due to the small beta penetration depth.
Table 3. Radionuclide activities to deliver 263 Gy tumour dose.
Radionuclides Dose per activity (Gy/GBq) Dose factor

Equivalent activity (GBq)

90

27.62

1

1.82

153

6.04

0.219

8.32

166

8.62

0.312

5.83

177

11.30

0.409

4.44

Y
Sm
Ho
Lu

The remaining radiation that escaped from the tumour was absorbed by the normal liver. As shown
in table 4, the other radionuclides contribute to lower normal liver doses which are advantageous as it
allows for normal liver tissue sparing. This was due to the shorter beta ranges (lower beta energies), and
thus, only a small fraction of these energies reaching the normal liver volume as compared to 90Y.
Table 4. Normal liver dose (Gy) as a result of 263 Gy tumour dose.
Radionuclides

Absorbed dose (Gy)

90

2.92 ± 0.05

Y

153

Sm
Ho

166
177

Lu

2.30 ± 0.01
2.20 ± 0.06
1.59 ± 0.02

0.8
Y-90
Sm-153
Ho-166
Lu-177

Absorbed dose (Gy)

0.7

0.6
0.5
0.4
0.3
0.2
0.1
0

Organs

Figure 2. Organ doses as a result of 263 Gy tumour dose from 90Y, 153Sm, 166Ho and 177Lu. L: left, R:
right, ULI: upper large intestines, LLI: lower large intestines.
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The absorbed doses to the other organs from the various radionuclides are shown in figure 2. It was
observed that the highest organ doses were from 153Sm followed by 177Lu, however all doses were still
far below the maximum tolerance limit, i.e. 60, 23 and 17.5 Gy for adrenal glands, kidneys and lungs,
respectively. The absorbed doses to these organs were found to be less than 1 Gy, and were affected by
the energy of the gamma emissions, the half-life of the radionuclides, the distance from the liver and the
organs masses.
Even though the absorbed doses to organs found in this study were lower than 1 Gy, it should be
noted that they may be higher when more complicated cases are being simulated i.e. larger tumour hence
higher activity, as well as the presence of normal liver uptake and lung or extrahepatic shunting. Further
work to simulate more complex situations should be carried out and the maximum limit for treatment
eligibility should be determined.
4. Conclusions
166
Ho, 177Lu and 153Sm offer the useful gamma emissions for post-procedure imaging. They show
potential as 90Y substitutes, delivering comparable tumour doses and lower normal liver doses, with
other organ doses far below the maximum tolerance limit.
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